EU MDR (Regulation (EU) 2017/745) is the European Union regulation governing the design, manufacture, and marketing of medical devices sold in the EU. It replaced the earlier Medical Device Directive, setting stricter rules for clinical evidence, risk management, technical documentation, and post-market surveillance across all device classes.
What is EU MDR (EU 2017/745)?
EU MDR stands for the European Union Medical Device Regulation, formally Regulation (EU) 2017/745. It became fully applicable on May 26, 2021, replacing the Medical Device Directive (93/42/EEC) and the Active Implantable Medical Devices Directive (90/385/EEC).
The regulation sets the legal requirements a device must meet to carry a CE mark and be placed on the EU market. It applies to manufacturers, authorized representatives, importers, and distributors, and it also captures certain products without a direct medical purpose, such as some aesthetic devices listed in Annex XVI.
Why EU MDR (EU 2017/745) matters in medical device development
EU MDR raises the evidence bar for market access. A device cannot be sold in the EU until it demonstrates conformity, so the regulation directly shapes design decisions, testing plans, and documentation from the first feasibility study onward.
The stakes are high. A Notified Body can refuse or withdraw a certificate, national competent authorities can order corrective actions or recalls, and non-conforming products can be pulled from the market. Each of these outcomes carries cost, delay, and reputational damage.
Planning for EU MDR early also protects timelines. Retrofitting clinical evaluation reports, risk files, or usability data late in a program is slow and expensive. Teams that build the required evidence as they go reach certification faster than those treating compliance as a final gate.
How the EU MDR (EU 2017/745) works
Compliance follows a defined route from classification through certification and ongoing surveillance:
- Classify the device. Apply the rules in Annex VIII to assign Class I, IIa, IIb, or III based on risk. Classification determines how much Notified Body scrutiny applies.
- Meet the General Safety and Performance Requirements. Demonstrate conformity with the GSPR in Annex I, supported by risk management to ISO 14971 and usability engineering to IEC 62366-1.
- Build the technical documentation. Assemble the Annex II and III files: design, verification, validation, clinical evaluation, labeling, and manufacturing information. Software devices add lifecycle evidence to IEC 62304.
- Complete conformity assessment. For most Class IIa and higher devices, a Notified Body audits the quality system (typically ISO 13485) and reviews the technical file before issuing a certificate. Most Class I devices are self-declared.
- Affix the CE mark and register. Apply the CE mark, generate Unique Device Identifiers, and register the device and actors in EUDAMED.
- Maintain post-market surveillance. Run PMS and post-market clinical follow-up, file periodic safety update reports, and report incidents through vigilance.
Transition periods extended by Regulation (EU) 2023/607 and 2024/1860 let some legacy devices remain on the market into 2027 and 2028, subject to conditions. Four core EUDAMED modules become mandatory on May 28, 2026.
Common challenges and best practices
The most common failure point is weak clinical evidence. Many manufacturers underestimate what a Notified Body expects from a clinical evaluation report, then face review questions that stall certification. Start the clinical evaluation plan early and keep it live throughout development.
Technical documentation gaps are the next hurdle. Reviewers look for a clear thread from user needs to design inputs, outputs, verification, and risk controls. Traceability that is built as work happens is far easier to defend than one reconstructed before an audit.
Watch the regulatory landscape without overreacting to it. A December 2025 Commission proposal, COM(2025) 1023, aims to simplify parts of the MDR, but it is still moving through the legislative process and is not yet law. Plan against the current rules, and treat the proposal as a signal, not a deadline.
How SJML helps with EU MDR (EU 2017/745)
SJML supports medical device manufacturers through EU MDR conformity as part of its Compliance-as-a-Service offering. Its QARA team handles regulatory strategy and device classification, CE marking, and technical file preparation, along with clinical evaluation planning through CEP and CER development. SJML also builds and remediates ISO 13485 quality systems, maintains ISO 14971 risk management files, and supports post-market surveillance, vigilance reporting, and EUDAMED registration. Working across India, the U.S., and Europe, SJML helps startups and established OEMs move devices toward EU market access with the documentation a Notified Body expects.
Frequently asked questions
Yes. EU MDR became fully applicable on May 26, 2021, and remains the governing law for medical devices in the EU. Staggered transition periods, extended by Regulation (EU) 2023/607 and 2024/1860, let some legacy devices certified under the old directives stay on the market into 2027 and 2028 if manufacturers meet the conditions. A December 2025 simplification proposal is under review but is not yet law.
EU MDR replaced the Medical Device Directive (93/42/EEC) and the Active Implantable Medical Devices Directive (90/385/EEC). It applies stricter clinical evidence requirements, widens scope to some products without a medical purpose, reclassifies many software and implantable devices, mandates unique device identification and EUDAMED registration, and strengthens post-market surveillance. Compliance under the old directives does not automatically satisfy the EU MDR.
EU MDR covers all medical devices placed on the EU market, grouped into risk-based classes: Class I, Class IIa, Class IIb, and Class III. Classification follows the rules in Annex VIII and drives the conformity assessment route. Higher-risk classes require Notified Body involvement, while most Class I devices can be self-certified by the manufacturer under the regulation.
EUDAMED is the European database on medical devices, holding data on manufacturers, devices, certificates, and market surveillance. Four core modules become mandatory on May 28, 2026: actor registration, UDI and device registration, Notified Bodies and certificates, and market surveillance. Manufacturers selling in the EU must register the required data by that date, independent of the pending simplification proposal.
Related terms
- CE Marking
- Conformity Assessment
- Notified Body
- Clinical Evaluation Report (CER)
- EUDAMED
